CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: First-in-Human Results, Biodistribution and Preliminary Dosimetry Estimations
DOI 10.1055/s-0040-1708131
Bibliografische Angaben
Nachweis in CareLit
Autor:innenRP Baum, C Smerling, C Schuchardt, A Singh, A Eismant, A Mishra, D Müller, D Zboralski, F Osterkamp, A Höhne, U Reineke, HR Kulkarni
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe02/2020
Jahrgang / SeitenJg. 59
Kernaussage aus der Literatur
Abstract-Vorschau
Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: First-in-Human Results, Biodistribution and Preliminary Dosimetry Estimations
Zitieren
Zitierempfehlung
RP Baum, C Smerling, C Schuchardt, A Singh, A Eismant, A Mishra, D Müller, D Zboralski, F Osterkamp, A Höhne, U Reineke, HR Kulkarni (2020) Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: First-in-Human Results, Biodistribution and Preliminary Dosimetry Estimations. Nuklearmedizin - NuclearMedicine, 59 (02). https://doi.org/10.1055/s-0040-1708131
Mit CareLit weiterarbeiten